Sign inJoin waitlistJoin the waitlist

Harriet Eldredge-Hindy

Associate Professor · Medical University of South Carolina College of Medicine

Credentials: · · · · · ·

History

Medical University of South Carolina College of Medicine
Present

Radiation Oncology
Thomas Jefferson University Hospital
2011–2015
Preliminary or Transitional Year
2010–2011
Sidney Kimmel Medical College at Thomas Jefferson University
2006–2010
Georgetown University

Research

Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
International journal of radiation oncology · 2017 · 94 citations
Species dependence on plasma protein binding and relaxivity of the gadolinium-based MRI contrast agent MS-325
Investigative Radiology · 2006 · First of 5 authors · 63 citations
Patients Undergoing Radiation Therapy Are at Risk of Financial Toxicity: A Patient-based Prospective Survey Study
International journal of radiation oncology · 2018 · 63 citations

Adam Dicker
7 papers
Joshua Palmer
6 papers · 2 as a resident
DM
Daniel Metzinger
5 papers
Maria Werner-Wasik
5 papers
ST
Sarah Todd
5 papers · 5 as a fellow
Scott Silva
5 papers
David Andrews
4 papers
James Evans
4 papers
Kelly McMasters
4 papers
Leonid Reshko
4 papers · 4 as a resident
Nicolás Ajkay
4 papers
Pramila Anne
4 papers

Clinical trials

Stereotactic Ablative Radiation Therapy for Prostate Cancer
Principal investigator · Active not recruiting
Medical University of South Carolina
2023–2028
Accelerated Hypofractionated Radiotherapy (AHF-RT) for the Treatment of Breast Cancer
Principal investigator · Completed
University of Louisville
2011–2021
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Site PI · Recruiting · Phase 2
NRG Oncology
2023–2033
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Site PI · Recruiting · Phase 3
NRG Oncology
2021–2041